MCT® is a biodegradable depot adjuvant developed primarily for use in short-course subcutaneous allergy immunotherapy (AIT), in combination with native allergens or modified allergens (allergoids) with or without Monophosphoryl Lipid A® (MPL®, a Toll-like receptor 4 agonist) (48). The gene discussed is TLR4; the disease is Allergy.